1-[(2-Chlorophenyl)methyl]-1H-imidazole-5-carboxaldehyde | 655235-92-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-[(2-Chlorophenyl)methyl]-1H-imidazole-5-carboxaldehyde
• 英文别名: 3-[(2-chlorophenyl)methyl]imidazole-4-carbaldehyde
• CAS: 655235-92-0
• 化学式: C₁₁H₉ClN₂O
• 分子量: 220.658
• InChiKey: GZYJGOFUCIHFAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-氨基-[1,1'-联苯]-2-甲酸甲酯 、 1-[(2-Chlorophenyl)methyl]-1H-imidazole-5-carboxaldehyde 在 sodium cyanoborohydride 、 溶剂黄146 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 5-{[3-(2-chlorobenzyl)-3H-imidazol-4-ylmethyl]-amino}-biphenyl-2-carboxylic acid methyl ester
  参考文献：
  名称：

  Structurally Simple Inhibitors of Lanosterol 14α-Demethylase Are Efficacious In a Rodent Model of Acute Chagas Disease

  摘要：

  We report structure-activity studies of a large number of dialkyl imidazoles as inhibitors of Trypanosoma cruzi lanosterol-14 alpha-demethylase (L14DM). The compounds have a simple structure compared to posaconazole, another L14DM inhibitor that is an anti-Chagas drug candidate. Several compounds display potency for killing T cruzi amastigotes in vitro with values of EC50 in the 0.4-10 nM range. Two compounds were selected for efficacy studies in a mouse model of acute Chagas disease. At oral doses of 20-50 mg/kg given after establishment of parasite infection, the compounds reduced parasitemia in the blood to undetectable levels, and analysis of remaining parasites by PCR revealed a lack of parasites in the majority of animals. These dialkyl imidazoles are substantially less expensive to produce than posaconazole and are appropriate for further development toward an anti-Chagas disease clinical candidate.

  DOI：

  10.1021/jm900030h
• 作为产物：
  描述：

  2-氯苄溴 、 1-三苯甲基咪唑-4-甲醛 以 乙腈 为溶剂， 生成 1-[(2-Chlorophenyl)methyl]-1H-imidazole-5-carboxaldehyde
  参考文献：
  名称：

  Structurally Simple Inhibitors of Lanosterol 14α-Demethylase Are Efficacious In a Rodent Model of Acute Chagas Disease

  摘要：

  We report structure-activity studies of a large number of dialkyl imidazoles as inhibitors of Trypanosoma cruzi lanosterol-14 alpha-demethylase (L14DM). The compounds have a simple structure compared to posaconazole, another L14DM inhibitor that is an anti-Chagas drug candidate. Several compounds display potency for killing T cruzi amastigotes in vitro with values of EC50 in the 0.4-10 nM range. Two compounds were selected for efficacy studies in a mouse model of acute Chagas disease. At oral doses of 20-50 mg/kg given after establishment of parasite infection, the compounds reduced parasitemia in the blood to undetectable levels, and analysis of remaining parasites by PCR revealed a lack of parasites in the majority of animals. These dialkyl imidazoles are substantially less expensive to produce than posaconazole and are appropriate for further development toward an anti-Chagas disease clinical candidate.

  DOI：

  10.1021/jm900030h

文献信息

• Imidazolyl-alkenoic acids
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0403158A2

  公开（公告）日：1990-12-19

  Angiotensin II receptor antagonists having the formula: which are useful in requlating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma, pharmaceutical compositions including these antagonists, and methods of using these compounds to produce angiotensin II receptor antagonism in mamnals.

  式的血管紧张素 II 受体拮抗剂： 可用于调节高血压和治疗充血性心力衰竭、肾功能衰竭和青光眼的拮抗剂，包括这些拮抗剂的药物组合物，以及使用这些化合物在动物体内产生血管紧张素 II 受体拮抗作用的方法。
• Substituted 5-((tetrazolyl)alkenyl)-imidazoles
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0425211A1

  公开（公告）日：1991-05-02

  Angiotensin II receptor antagonists having the formula: which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma, pharmaceutical compositions including these antagonists, and methods of using these compounds to produce angiotensin II receptor antagonism in mammals.

  式的血管紧张素 II 受体拮抗剂： 用于调节高血压和治疗充血性心力衰竭、肾功能衰竭和青光眼的血管紧张素 II 受体拮抗剂，包括这些拮抗剂的药物组合物，以及使用这些化合物在哺乳动物体内产生血管紧张素 II 受体拮抗作用的方法。
• US5177096A
  申请人：——

  公开号：US5177096A

  公开（公告）日：1993-01-05